Inivata and collaborators to present data that further validate the application of its RaDaR™ MRD and InVisionFirst®-Lung assays at the ESMO Congress 2021
Research Triangle Park, NC, USA and Cambridge, UK, 9 September 2021 -- Inivata, a leader in liquid biopsy, alongside collaborators, will present new data on its RaDaR™ assay for the detection of molecular residual disease (MRD) and recurrence and on its InVisionFirst®-Lung liquid biopsy test at the European Society for Medical Oncology (ESMO) Congress, taking place on 16-21 September 2021.
Inivata will present two posters highlighting data for RaDaR as a highly sensitive, personalized assay for the detection of residual disease and recurrence in head and neck squamous cell carcinoma (HNSCC) and
new data in early-stage breast cancer. The assay allows both detection of residual disease following curative intent or definitive treatment and early detection of relapse. Tracking a set of up to 48 tumor-specific variants in a patient, RaDaR is built on Inivata’s proven InVision® liquid biopsy platform technology. The two other posters will showcase new clinical utility data on InVisionFirst-Lung, Inivata’s highly sensitive 37 gene liquid biopsy test related to the care of patients with advanced NSCLC. In this real-time clinical utility study, liquid biopsy supported treatment selection in 68% patients.
Abstracts will be available on the ESMO website on Monday 13 September and accompanying posters will be available to view during the conference, between 16-21, September via the ESMO e-poster site, together with audio description.
Clive Morris, President of Inivata, said: “The clinical studies to date have shown that RaDaR can deliver exceptionally sensitive detection of ctDNA in MRD settings across multiple tumor types with the potential to transform current cancer treatment regimens. We look forward to presenting findings on these latest studies as we continue to highlight the growing clinical evidence in support of this highly sensitive assay. Alongside this we will present clinical utility data for InVisionFirst-Lung in non-small cell lung cancer patients.”
Details of the abstracts are as follows:
Title: Personalized circulating cell-free tumor DNA analysis for detection of minimal residual disease and recurrence in patients with head and neck squamous cell carcinoma
Abstract No: #2361
Title: A personalized sequencing approach for liquid biopsy-based detection of recurrent disease in early-stage breast cancer
Abstract No: #3446
Title: Clinical utility of ctDNA for detection of EGFR, ALK, BRAFV600E alterations and resistance mutations in patients with NSCLC at failure to targeted therapy
Abstract No: #3447
Title: Real-time clinical utility of ctDNA genomic alterations in untreated patients with advanced NSCLC
Abstract No: #3697
Inivata is the liquid biopsy-focused subsidiary of the NeoGenomics, Inc (NASDAQ: NEO) Group. Inivata’s InVision® liquid biopsy platform unlocks essential genomic information from a simple blood draw to guide and personalize cancer treatment, monitor response and detect relapse. Inivata’s technology is based on pioneering research from the Cancer Research UK Cambridge Institute, University of Cambridge. The personalized RaDaR™ assay allows the highly sensitive detection of residual disease and recurrence and has been granted Breakthrough Device Designation by the US FDA. The commercially available InVisionFirst®-Lung test offers best-in-class sensitivity and turnaround and provides molecular insights that enable clinicians to make more informed treatment decisions for advanced NSCLC patients. Inivata is partnering with pharmaceutical, biotechnology companies and commercial partners in a range of early and late-stage cancer development programs across a range of cancer types. Inivata has a CLIA certified, CAP accredited laboratory in Research Triangle Park, NC and R&D laboratories in Cambridge, UK.
RaDaR is Inivata’s assay for the detection of molecular residual disease (MRD) and recurrence. Built on Inivata’s proven InVision® liquid biopsy platform technology, RaDaR is a highly sensitive personalized assay that tracks a set of up to 48 tumor-specific variants in a patient using a liquid biopsy, allowing both detection of residual disease following curative intent or definitive treatment, and early detection of relapse. RaDaR has been granted Breakthrough Device Designation by the US FDA.
Consilium Strategic Communications
Chris Gardner/Angela Gray/Genevieve Wilson
Alix Floyd (US)
email@example.com +44 (0)20 3709 5700
firstname.lastname@example.org +44 (0)7900 430235